The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Randomized controlled trials and real-world data: differences and similarities to untangle literature data
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
These reviews may allow for the evaluation of adverse events and long-term effects after exposure to healthcare interventions.
“Moreover, these reviews may allow for the evaluation of adverse events and long-term effects after exposure to healthcare interventions [3].”
From RoBANS 2: A Revised Risk of Bias Assessment Tool for Nonrandomized Studies of Interventions (2023) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Comparison of Evidence of Treatment Effects in Randomized and Nonrandomized Studies
Ioannidis, J. P. A. (2001) · JAMA · doi:10.1001/jama.286.7.821 · Cited by 919
Flagged first, then by citations
Research works printed but not linked: 20
- Rothwell, 2005, External validity of randomised controlled trials: “to whom do the results of this trial apply?”, Lancet, 365, 82, 10.1016/S0140-6736(04)17670-8 · DOI · Paper page
- Kennedy-Martin, 2015, A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results, Trials, 16, 495, 10.1186/s13063-015-1023-4 · DOI · Paper page
- Zink, 2006, Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials, Arthritis Rheum, 54, 3399, 10.1002/art.22193 · DOI
- Vashisht, 2016, Generalizability of patients with rheumatoid arthritis in biologic agent clinical trials, Arthritis Care Res, 68, 1478, 10.1002/acr.22860 · DOI
- Nair, 2014, Generalization and extrapolation of treatment effects from clinical studies in rheumatoid arthritis, Arthritis Care Res, 66, 998, 10.1002/acr.22269 · DOI
- Nordon, 2016, The “efficacy-effectiveness gap”: historical background and current conceptualization, Value Health, 19, 75, 10.1016/j.jval.2015.09.2938 · DOI · Paper page
- Haynes, 1999, Can it work? Does it work? Is it worth it?, BMJ, 319, 652, 10.1136/bmj.319.7211.652 · DOI
- Martin, 2005, Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials, Clin Exp Rheumatol, 23, 80
- Gibofsky, 2006, Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study, Curr Med Res Opin, 22, 169, 10.1185/030079906X80341 · DOI
- Weaver, 2006, Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry, Curr Med Res Opin, 22, 185, 10.1185/030079905X65510 · DOI
- Blumenauer, 2002, Infliximab for the treatment of rheumatoid arthritis, Cochrane Database Syst Rev, CD003785
- Wolfe, 2005, Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness, Rheumatology, Suppl 4, iv18, 10.1093/rheumatology/kei056 · DOI
- Sathasivam, 2008, Statin induced myopathy, BMJ, 337, a2286, 10.1136/bmj.a2286 · DOI
- Elliott, 2016, Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes, Diabetes Ther, 7, 45, 10.1007/s13300-016-0157-z · DOI
- Askling, 2011, Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data, Pharmacoepidemiol Drug Saf, 20, 119, 10.1002/pds.2046 · DOI
- Maini, 1999, Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, Lancet, 354, 1932, 10.1016/S0140-6736(99)05246-0 · DOI
- Chen, 2016, Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses, Clin Rheumatol, 35, 1, 10.1007/s10067-015-3115-7 · DOI
- Mercer, 2017, Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis, Ann Rheum Dis, 76, 497, 10.1136/annrheumdis-2016-209389 · DOI
- Keane, 2001, Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent, N Engl J Med, 345, 1098, 10.1056/NEJMoa011110 · DOI
- Favalli, 2014, Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs, Biomed Res Int, 2014, 831603, 10.1155/2014/831603 · DOI
Cited by
Sorted by citations
Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users
Silva, J. D., Lepore, G., Battelino, T., Arrieta, A., Castañeda, J., Grossman, B., Shin, J., & Cohen, O. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0203 · Cited by 229
Mehta, A., Niles, A. N., Vargas, J. H., Marafon, T., Couto, D. D., & Gross, J. J. (2021) · Journal of Medical Internet Research · doi:10.2196/26771 · Cited by 143
RoBANS 2: A Revised Risk of Bias Assessment Tool for Nonrandomized Studies of Interventions
Seo, H.-J., Kim, S. Y., Lee, Y. J., & Park, J.-E. (2023) · Korean Journal of Family Medicine · doi:10.4082/kjfm.23.0034 · Cited by 128
Metadata
- Authors
- Monti, S., Grosso, V., Todoerti, M., & Caporali, R.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-10-01
- Volume
- 57
- Issue
- Supplement_7
- Pages
- vii54-vii58
- ISSN
- 1462-0324
- 1462-0332
- Cited by
- 170
- References
- 2
- Language
- en
- Funders
- Edizioni Internazionali srl, Pavia
- AbbVie
- Brystol Meyer Squibb
- Celgene
- Lilly
- Pfizer
- Roche, Merck Sharp & Dohme, Novartis, Sanofi
- Union Chimique Belge
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
